Pharma penny stock under Rs 50 in focus as company inaugurates its state-of-the-art R&D center in Hyderabad
From Rs 34.51 per share (52-week low) to Rs 56.15 per share, the stock is up by 55.3 per cent.
Today, shares of Sigachi Industries Ltd gained 2.43 per cent to Rs 56.15 per share from its previous closing of Rs 54.82 per share. The company has a market cap of Rs 1,822 crore and has delivered good profit growth of 28 per cent CAGR over the last 5 years. From Rs 34.51 per share (52-week low) to Rs 56.15 per share, the stock is up by 55.3 per cent.
Sigachi Industries Limited, a prominent pharmaceutical company, has officially opened its new, state-of-the-art Research and Development (R&D) Center in Hyderabad. This pivotal facility aims to bring API development and analytical capabilities under one roof, significantly accelerating product development and driving long-term growth in regulated markets. The center is poised to be crucial in advancing Sigachi's innovation roadmap and improving its responsiveness to global regulatory demands.
The Hyderabad R&D Center is strategically designed to strengthen API development, ensure regulatory alignment through advanced systems for synthesis and global filings, and fuel pipeline growth. This will be supported by a targeted investment of up to USD 1 million for priority APIs and complex intermediates. The center will also focus on effectively aligning the pharma product portfolio with strategic therapeutic segments and empowering a high-impact research team to lead global market development efforts.
Commenting on this development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated “This R&D Center is a strategic asset that will significantly strengthen our development capabilities and enable us to respond swiftly to market needs, it reflects our focus on building operational depth and creating long-term value for our customers, partners, and stakeholders in an evolving global pharmaceutical environment.”
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.
About the Company
Sigachi Industries Limited, a publicly traded pharmaceutical company listed on NSE and BSE, is a global leader in providing high-quality excipients, vitamin-mineral nutrient blends, APIs, and O&M services. With over 35 years of industry expertise, Sigachi has built a strong reputation as a trusted partner for pharmaceutical and nutraceutical companies worldwide. They specialise in innovative solutions for food stability, fortification, and nutrition, offering tailored blends of vitamins, minerals, and other ingredients to meet the evolving needs of consumers. By utilising advanced technologies like blending, encapsulation, and spray drying, Sigachi empowers food manufacturers to create products with superior taste, quality, and nutritional value, contributing to a healthier and happier world.
The company announced positive Quarterly Results (Q4FY25) and annual results (FY25). According to quarterly results, revenue increased by 23 per cent to Rs 128.21 crore, EBITDA increased by 30 per cent to Rs 30.75 crore and net profit increased by 7 per cent to Rs 16.17 crore in Q4FY25 compared to Q4FY24. In its annual results, revenue increased by 22 per cent to Rs 488.24 crore, EBITDA increased by 36 per cent to Rs 120.50 crore and consolidated PAT increased by 22 per cent to Rs 70.46 crore in FY25 compared to FY24.
Disclaimer: The article is for informational purposes only and not investment advice.